Gossamer Bio, Inc. (GOSS) — 10-Q Filings

10-Q Filings (5)

• Gossamer Bio's Losses Mount Amid Soaring R&D, Cash Dwindles — Nov 5, 2025 Risk: high
  Gossamer Bio, Inc. (GOSS) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $123.1 million, a substantial rise
• Gossamer Bio Narrows Q2 Loss Amidst Zero Revenue — Aug 5, 2025 Risk: high
  Gossamer Bio, Inc. reported no revenue from contracts with collaborators for the three and six months ended June 30, 2025, consistent with the prior year's peri
• Gossamer Bio Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Gossamer Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported revenue from contracts with collaborators and license and servi
• Gossamer Bio Reports Flat Q2 Revenue — Aug 12, 2024 Risk: medium
  Gossamer Bio, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported revenue from contracts with collaborators of $0.0 million for the se
• Gossamer Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: low
  Gossamer Bio, Inc. (GOSS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Gossamer Bio, Inc. filed a 10-Q report for the period ending March 31, 20

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX